Molecular prescreening to select patient population in early clinical trials

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Nature Reviews Clinical Oncology

• Publication date

  2012-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1038/nrclinonc.2012.48PMID 22473105
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cancer genomics: technology, discovery, and translation.

  2012cited by this paper
• Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

  2012cited by this paper
• Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors.

  2012cited by this paper
• Human cancers express mutator phenotypes: origin, consequences and targeting

  2011cited by this paper
• Integrated Genomic Analyses of Ovarian Carcinoma

  2011cited by this paper
• Circulating tumor cells as pharmacodynamic biomarker in early clinical oncological trials.

  2011cited by this paper
• Parallel anticancer drug development and molecular stratification to qualify predictive biomarkers: dealing with obstacles hindering progress.

  2011cited by this paper
• Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study

  2011cited by this paper
• The BATTLE trial: personalizing therapy for lung cancer.

  2011cited by this paper
• Window-of-opportunity trials to evaluate clinical activity of new molecular entities in oncology.

  2011cited by this paper
• Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.

  2011cited by this paper
• Trastuzumab-DM1: building a chemotherapy-free road in the treatment of human epidermal growth factor receptor 2-positive breast cancer.

  2011cited by this paper
• Personalized treatment of lung cancer.

  2011cited by this paper
• Improved survival with vemurafenib in melanoma with BRAF V600E mutation.

  2011cited by this paper
• WIN Consortium—challenges and advances

  2011cited by this paper
• A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors

  2011cited by this paper
• Novel Therapeutic Targets in Non-small Cell Lung Cancer

  2011cited by this paper
• mRNA and microRNA Expression Profiles in Circulating Tumor Cells and Primary Tumors of Metastatic Breast Cancer Patients

  2011cited by this paper
• Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

  2011cited by this paper
• Cancer Pharmacogenomics

  2011cited by this paper
• Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors

  2011cited by this paper
• Personalized medicine in a phase I clinical trials program: The M. D. Anderson Cancer Center Initiative.

  2011cited by this paper
• Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies.

  2011cited by this paper
• Targeted therapies: Chemotherapy-free option for relapsed patients with breast cancer

  2011cited by this paper
• International network of cancer genome projects

  2010cited by this paper
• Quantifying EGFR alterations in the lung cancer genome with nanofluidic digital PCR arrays.

  2010cited by this paper
• Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study.

  2010cited by this paper
• Distant Metastasis Occurs Late during the Genetic Evolution of Pancreatic Cancer

  2010cited by this paper
• Genome Remodeling in a Basal-like Breast Cancer Metastasis and Xenograft

  2010cited by this paper
• Mapping copy number variation by population scale genome sequencing

  2010cited by this paper
• Tumor heterogeneity: causes and consequences.

  2010cited by this paper
• COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

  2010cited by this paper
• Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer

  2010cited by this paper
• Prognostic Value of Circulating Mutant DNA in Unresectable Metastatic Colorectal Cancer

  2010cited by this paper
• Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

  2010cited by this paper
• Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers.

  2010cited by this paper
• Envisioning the future of early anticancer drug development

  2010cited by this paper
• K-ras mutational status predicts poor prognosis in unresectable pancreatic cancer.

  2010cited by this paper
• BATTLE to personalize lung cancer treatment

  2010cited by this paper
• An adaptive randomized discontinuation trial of XL184 (BMS-907351) in patients (pts) with advanced solid tumors.

  2010cited by this paper
• First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors.

  2010cited by this paper
• Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval.

  2010cited by this paper
• Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine

  2010cited by this paper
• Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

  2009cited by this paper
• Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941

  2009cited by this paper
• Clinical Studies of Histone Deacetylase Inhibitors

  2009cited by this paper
• Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study

  2009cited by this paper
• Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors.

  2009cited by this paper
• Project Zero Delay: a process for accelerating the activation of cancer clinical trials.

  2009cited by this paper
• Microvesicles: Messengers and mediators of tumor progression

  2009cited by this paper
• Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449.

  2009cited by this paper
• The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.

  2009cited by this paper
• Genotyping technologies for genetic research.

  2009cited by this paper
• Detection of mutations in EGFR in circulating lung-cancer cells.

  2008cited by this paper
• Anti-VEGF therapy: the search for clinical biomarkers

  2008cited by this paper
• Comprehensive genomic characterization defines human glioblastoma genes and core pathways

  2008cited by this paper
• NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.

  2008cited by this paper
• Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235.

  2008cited by this paper
• The Catalogue of Somatic Mutations in Cancer (COSMIC)

  2008cited by this paper
• Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling

  2007cited by this paper
• A phase II study of the dual MET/VEGFR2 inhibitor XL880 in patients (pts) with papillary renal carcinoma (PRC)

  2007cited by this paper
• Trastuzumab--mechanism of action and use in clinical practice.

  2007cited by this paper
• Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis

  2006cited by this paper
• Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.

  2006cited by this paper
• Novel therapeutic targets

  2006cited by this paper
• Lapatinib plus capecitabine for HER2-positive advanced breast cancer.

  2006cited by this paper
• Non-small cell lung cancer: Clinical practice guidelines in oncology

  2006cited by this paper
• Risks and benefits of phase 1 oncology trials, 1991 through 2002.

  2005cited by this paper
• The PIK3CA gene is mutated with high frequency in human breast cancers

  2004cited by this paper
• The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website

  2004cited by this paper
• The phase III trial in the era of targeted therapy: unraveling the "go or no go" decision.

  2003cited by this paper
• Go or No-Go?

  2003cited by this paper
• Methods of molecular analysis: mutation detection in solid tumours

  2002cited by this paper
• Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.

  2002cited by this paper
• ERK1/2 phosphorylation: a biomarker analysis within a phase I study with the new Raf kinase inhibitor BAY43-9006.

  2002cited by this paper
• On telomere shortening in soft-tissue tumors

  1998cited by this paper
• MDM2 amplification and loss of heterozygosity at Rb and p53 genes: no simultaneous alterations in the oncogenesis of liposarcomas

  1998cited by this paper
• Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.

  1996cited by this paper
• p53 Mutation and MDM2 amplification in human soft tissue sarcomas.

  1993cited by this paper

• Transcriptomics analysis unveils the complex interplay between diabetes and hypertension in regulating renal cell carcinoma pathway followed by pancreatic metastasis

  2025cites this paper
• First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study

  2021cites this paper
• Ciliary Genes in Renal Cystic Diseases

  2020cites this paper
• Evolving Landscape of Molecular Prescreening Strategies for Oncology Early Clinical Trials

  2020cites this paper
• New clinical trial designs in the era of precision medicine

  2019cites this paper
• Integrating clinical, molecular, proteomic and histopathological data within the tissue context: tissunomics

  2019cites this paper
• Optimised Tumour Sampling and Processing by a Multidisciplinary Approach for an Accurate Diagnosis in Non-Small Cell Lung Cancer

  2019cites this paper
• Relevance of a molecular tumour board (MTB) for patients’ enrolment in clinical trials: experience of the Institut Curie

  2018cites this paper
• Beyond molecular tumor heterogeneity: protein synthesis takes control

  2018cites this paper
• Evaluating Clinical Genome Sequence Analysis by Watson for Genomics

  2018cites this paper
• Global trends in the distribution of cancer types among patients in oncology phase I trials, 1991–2015

  2018cites this paper
• Cancer Immunotherapy, Part 3: Challenges and Future Trends.

  2017cites this paper
• Use of the Total Cancer Care System to Enrich Screening for CD30-Positive Solid Tumors for Patient Enrollment Into a Brentuximab Vedotin Clinical Trial: A Pilot Study to Evaluate Feasibility

  2017influential citation
• Clinical research in small genomically stratified patient populations.

  2017cites this paper
• Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma

  2017cites this paper
• Bayesian Baskets: A Novel Design for Biomarker-Based Clinical Trials.

  2017cites this paper
• The current use and attitudes towards tumor genome sequencing in breast cancer

  2016cites this paper
• Testing oncological treatments in the era of personalized medicine

  2016cites this paper
• Molecular screening programmes for precision medicine: lessons learned from personalized medicine trials

  2016cites this paper
• Review Article Current Challenges in Cancer Treatment

  2016cites this paper
• Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety.

  2016cites this paper
• New generation of breast cancer clinical trials implementing molecular profiling

  2016cites this paper
• Current Challenges in Cancer Treatment.

  2016cites this paper
• The changing landscape of phase I trials in oncology

  2016cites this paper
• Utility of a molecular prescreening program in advanced colorectal cancer for enrollment on biomarker-selected clinical trials.

  2016cites this paper
• Early Trial Discontinuation in Toxicity-Driven, Dose-Escalating, Phase I Cancer Trials: Occurrence, Outcomes and Predictive Factors

  2016cites this paper
• Evaluation of targeted therapies in advanced breast cancer: the need for large-scale molecular screening and transformative clinical trial designs

  2016cites this paper
• Is Personalized Medicine Here?

  2016cites this paper
• A framework for prescription in exercise-oncology research†

  2015cites this paper
• The changing landscape of phase I trials in oncology.

  2015cites this paper
• The Personalization of Therapy: Molecular Profiling Technologies and Their Application.

  2015cites this paper
• Clinical Trials of Precision Medicine through Molecular Profiling: Focus on Breast Cancer.

  2015cites this paper
• Biomarcadores farmacodinámicos y predictivos de respuesta en la toma de decisiones en ensayos clínicos Fase I de terapias dirigidas contra el cáncer

  2015cites this paper
• Development of Fibroblast Growth Factor Receptor Inhibitors: Kissing Frogs to Find a Prince?

  2015cites this paper
• Utility of Next-Generation Sequencing in Cancer Drug Development and Clinical Trials

  2015cites this paper
• Optimal design of trials to demonstrate the utility of genomically‐guided therapy: Putting Precision Cancer Medicine to the test

  2015cites this paper
• Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.

  2014cites this paper
• Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial

  2014cites this paper
• Impact of tumor sequencing on the use of anticancer drugs

  2014cites this paper
• Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer.

  2014cites this paper
• Advances in the approach to novel drug clinical development for breast cancer

  2014cites this paper
• Standing the test of time: targeting thymidylate biosynthesis in cancer therapy

  2014cites this paper
• Tissue Biomarkers of Prognostic Significance in Hepatocellular Carcinoma

  2014cites this paper
• Individualizing breast cancer treatment-The dawn of personalized medicine.

  2014cites this paper
• The spectrum of clinical trials aiming at personalizing medicine.

  2014cites this paper
• Designing transformative clinical trials in the cancer genome era.

  2013cites this paper
• Tumour heterogeneity in the clinic

  2013cites this paper
• Targeting developmental pathways in children with cancer: what price success?

  2013cites this paper
• Biomarker-Guided Repurposing of Chemotherapeutic Drugs for Cancer Therapy: A Novel Strategy in Drug Development

  2013cites this paper
• Biomarker-driven patient selection for early clinical trials

  2013cites this paper
• Methodological assessment of HCC literature.

  2013cites this paper
• Luminal breast cancer: from biology to treatment

  2013cites this paper
• Personalized medicine: hype or reality.

  2013cites this paper
• Development of PI3K inhibitors: lessons learned from early clinical trials

  2013cites this paper
• Genomic medicine frontier in human solid tumors: prospects and challenges.

  2013cites this paper
• Integration of cancer genomics with treatment selection

  2013cites this paper
• Genomic Analyses across Six Cancer Types Identify Basal-like Breast Cancer as a Unique Molecular Entity

  2013cites this paper
• Personalized Genome, Current Status, and the Future of Pharmacogenomics

  2013cites this paper
• Biomarqueurs cellulaires circulants dans les cancers avancés

  2013cites this paper
• Luminal breast cancer: from biology

  2013cites this paper
• Depicting the evolving scenario of translational-guided drug development

  2012cites this paper
• Targeted therapies: Match-and-mix or match-and-miss?

  2012cites this paper
• Molecular Profiling of Patients with Colorectal Cancer and Matched Targeted Therapy in Phase I Clinical Trials

  2012cites this paper
• Molecular Medicine in Practice Molecular Pro fi ling of Patients with Colorectal Cancer and Matched Targeted Therapy in Phase I Clinical Trials

  2012cites this paper
• Clinical development of phosphatidylinositol 3-kinase inhibitors for cancer treatment

  2012cites this paper